Cathinone und synthetische Cannabinoide

NPS (neue psychoaktive Substanzen) sind eine Gruppe von Substanzen, die seit ca. 15 Jahren illegal und hauptsächlich über das Internet und die sozialen Medien vertreiben werden. Es handelt es sich um eine sehr heterogene Gruppe von Substanzen, die beim Konsum vielfältige psychotrope Wirkungen auslösen. Cathinone und synthetische Cannabinoide sind die am häufigsten konsumierten NPS. Ziel dieser Übersicht ist es, anhand von aktuellen Kenntnissen und Fallbeispielen die Pharmakologie, rechtlichen Aspekte und Risiken des Konsums von NPS übersichtsartig darzustellen und Hinweise auf Therapiemöglichkeiten zu geben.

Abstract

NPS (New Psychoactive Substances) are a group of substances that have been distributed illegally for about 15 years, mainly via the Internet and social media. It is a very heterogeneous group of substances that trigger a variety of psychotropic effects when consumed. Cathinones and synthetic cannabinoids are the most frequently used NPS. The aim of this overview is to provide an overview of the pharmacology, legal aspects, and risks of NPS consumption based on current knowledge and case studies and to provide indications of treatment options.

Key words

New Psychoactive Substances (NPS) - Synthetic Cannabinoids - Cathinones - Pharmacology - Therapy

Schlüsselwörter

Neue Psychoaktive Substanzen (NPS) - Synthetische Cannabinoide - Cathinone - Pharmakologie - Therapie

Publikationsverlauf

Artikel online veröffentlicht:
05. Mai 2022

• Literatur

• 1 Gomes de Matos E, Hannemann TV, Atzendorf J. et al. The consumption of new psychoactive substances and methamphetamine – analysis of data from 6 German federal states. Dtsch Arztebl Int 2018; 115: 49-55
• 2 European Monitoring Centre for Drugs and Drug Addiction. European Drug Report. Trends and Developments Luxembourg: Publications Office of the European Union; 2020
• 3 Hohmann N, Mikus G, Czock D. Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int 2014; 111: 139-147
• 4 Cottencin O, Rolland B, Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des 2014; 20: 4106-4111
• 5 Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol 2020; 94: 1085-1133
• 6 Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589
• 7 Auwärter V, Dresen S, Weinmann W. et al. ‛Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?. J Mass Spectrom 2009; 44: 832-837
• 8 Seitz NN, John L, Atzendorf J. et al. Kurzbericht Epidemiologischer Suchtsurvey 2015. Tabellenband: Konsum illegaler Drogen, multiple Drogenerfahrung und Hinweise auf Konsumabhängigkeit und -missbrauch nach Geschlecht und Alter im Jahr 2018. München: IFT Institut für Therapieforschung; 2019
• 9 Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 2015; 145: w14043
• 10 Graw M. Neuere Drogentrends aus rechtsmedizinischer Sicht. Spice, Badesalz, Legal Highs: harmlos sind hier nur die Namen. MMW Fortschr Med 2015; 157: 49-53
• 11 Scherbaum N, Schifano F, Bonnet U. New psychoactive substances (NPS) – a challenge for the addiction treatment services. Pharmacopsychiatry 2017; 50: 116-122
• 12 Martinotti G, Santacroce R, Papanti D. et al. Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset. CNS Neurol Disord Drug Targets 2017; 16: 567-575
• 13 Nakagawa Y, Suzuki T, Tayama S. et al. Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch Toxicol 2009; 83: 69-80
• 14 Schifano F, Napoletano F, Arillotta D. et al. The clinical challenges of synthetic cathinones. Br J Clin Pharmacol 2020; 86: 410-419
• 15 Hermanns-Clausen M, Kneisel S, Szabo B. et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108: 534-544
• 16 Cohen K, Weinstein AM. Synthetic and non-synthetic cannabinoid drugs and their adverse effects – A review from public health perspective. Front Public Health 2018; 6: 162
• 17 Zimmermann US, Winkelmann PR, Pilhatsch M. et al. Withdrawal phenomena and dependence syndrome after the consumption of ‘spice gold’. Dtsch Ärzteblatt Int 2009; 106: 464-467
• 18 Woo TM, Hanley J. ‘How do they look?’ Identification and treatment of common ingestions in adolescents. J Pediatr Health Care 2013; 27: 135-144
• 19 Antonowicz JL, Metzger AK, Ramanujam SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 2011; 33: 640
• 20 Abdulrahim D, Bowden-Jones O. on behalf of the NEPTUNE Expert Group. Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE); 2015
• 21 Donroe JH, Tetrault JM. Substance use, intoxication, and withdrawal in the critical care setting. Critical Care Clinics 2017; 33: 543-558
• 22 Eichler J, Rehm M, Azad SC. Legal highs (new psychoactive substances): What does the anesthesiologist need to know?. Anaesthesist 2020; 69: 599-608